Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Quantum X Labs appointed Yossi Cohen, the former Director of the Mossad and a strategic advisor to SoftBank, as President of its Scientific Advisory Board. Cohen will help guide the company's technological and commercial roadmap in quantum computing, cybersecurity, and sensing, specifically for defense and aerospace markets. The appointment aims to leverage Cohen's expertise in national security and global technology investments to scale the company's operations.
Zeo ScientifiX announced plans to expand its commercial and provider-support operations into Georgia and Tennessee. The move follows the enactment of new state laws in both jurisdictions that establish frameworks for stem cell and regenerative medicine therapies. The expansion aims to support healthcare providers with biologics, education, and implementation support as they navigate these evolving state-level regulatory environments.
American Express disclosed monthly delinquency and write-off statistics for its U.S. Consumer and U.S. Small Business card portfolios for the period ending August 31, 2026. As of August 31, total card balances held for investment reached $160.3 billion, with net write-off rates of 1.7% for U.S. Consumer and 2.2% for U.S. Small Business. These periodic metrics provide investors with insight into the credit quality and performance of the company's core lending portfolios.
BlossomHill Therapeutics announced updated Phase 1/2 SOLARA trial data for BH-30643 in patients with EGFR C797S-positive NSCLC, showing a 45% objective response rate and 88% disease control rate. The results, presented at the 2026 World Conference on Lung Cancer, demonstrate the drug's potential to overcome resistance to existing EGFR inhibitors in a population with no approved targeted therapies. The company plans to advance the candidate into a Phase 2 trial in 2027 following its recent FDA Fast Track designation.
Counterparty
International Association for the Study of Lung Cancer (IASLC)
Axon Enterprise $1B Debt Financing with JPMorgan Chase Bank, N.A.
Axon Enterprise announced a $1.0 billion offering of 0% convertible senior notes due 2031, with an additional $150 million over-allotment option. Concurrently, the company amended its credit agreement to increase its revolving credit facility from $300 million to $500 million and extended the maturity date to up to five years from closing.
Driven Brands announced that its Board of Directors has authorized a new $100 million share repurchase program, representing approximately 5% of its market capitalization. Alongside the buyback, the company updated its capital allocation strategy to include a long-term net leverage target of 2-3x Net Debt to Adjusted EBITDA while continuing to prioritize growth investments in its Take 5 brand.
FibroBiologics entered into a securities purchase agreement with its Chief Scientific Officer, Hamid Khoja, Ph.D., for a private placement of 298,508 shares and equal warrants. The offering is expected to raise approximately $0.5 million in gross proceeds for general corporate purposes and working capital. The securities were priced at $1.675 per unit, representing the previous day's closing bid price plus a warrant premium.
Rocket Pharmaceuticals announced alignment with the FDA on the pivotal Phase 2 trial design for RP-A501 in Danon disease, including a 12-patient pivotal population and 12-month co-primary endpoints. The FDA's review of initial safety data from the first three patients supports continued enrollment and dosing under a modified protocol, with completion of dosing expected by mid-2027.
Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute asthma exacerbations. The study met its key secondary endpoint with a statistically significant improvement in lung function (FEV1) at Day 7, and while the primary endpoint of treatment failure reduction (66%) did not reach statistical significance due to lower-than-projected event rates, the company plans to engage with the FDA for a Phase 3 program.
D-Wave Quantum Inc. announced its participation as a platinum sponsor at the Quantum World Congress 2026, where it will showcase its dual-platform quantum computing strategy. The company plans to present real-world results from its annealing systems and provide technical updates on its dual-rail gate-model architecture designed for error correction. Executives, including Chief Science Officer Dr. Robert Schoelkopf, will deliver a plenary address and participate in panels regarding quantum utility and federal policy.
Bread Financial provided a monthly performance update for August 2026, reporting a net principal loss rate of 6.40% and a delinquency rate of 5.36%. Both metrics showed improvement compared to August 2025, while average credit card and other loans grew 5.6% year-over-year to $18.6 billion.
Piedmont Realty Trust's operating partnership priced a private offering of $200 million in 2.875% exchangeable senior notes due 2031. The notes are senior unsecured obligations guaranteed by the company and include an initial exchange price of $12.65 per share, representing a 37.5% premium over the current stock price.
Truist Financial Corporation entered into an agreement to sell $5.5 billion of auto loans, representing substantially all assets of its Regional Acceptance Corporation (RAC) subsidiary. The transaction is part of a strategic exit from the near-prime auto lending business and is expected to generate $5.2 billion in net proceeds and $945 million in CET1 capital.
Vera Therapeutics announced positive topline results from the final efficacy analysis of its Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in patients with IgA nephropathy. The trial met all prespecified endpoints, demonstrating a 76% reduction in the risk of kidney disease progression and stabilization of kidney function (eGFR) through 104 weeks. The company plans to submit a supplemental BLA for full FDA approval in the fourth quarter of 2026.
Rocket Lab Signs $1.94B M&A Deal with Iridium Communications Inc.
Rocket Lab provided a status and financing update on its pending acquisition of Iridium Communications, announcing the deal is now fully funded. The company completed a $1.944 billion ATM equity offering and amended Iridium's existing $1.775 billion credit facility to permit the change of control, allowing Rocket Lab to terminate a previous $3.6 billion bridge facility.
Forgent Power Solutions reported record fiscal fourth quarter and full year 2026 results, with annual revenue growing 89% to $1.42 billion and net income rising 508% to $106 million. The company ended the year with an all-time high backlog of $3.0 billion and announced a $35 million investment to expand manufacturing capacity in Tijuana, Mexico.
Term
FY2026
Earnings call
Sep 15, 2026, 11:00 AM ET
“Momentum in electrical distribution equipment remains robust, and Forgent’s products and solutions continue to gain traction with customers. We booked more than $1.5 billion of orders in the fourth quarter — an amount that exceeded our total revenue for the full fiscal year — highlighting the strength of our offerings. Our performance demonstrates that Forgent is not only benefiting from industry growth, but also gaining share and significantly outpacing the broader market”
Transocean Wins $80M Contract from undisclosed operator
Transocean's ultra-deepwater drillship, Deepwater Conqueror, was awarded a two-well contract for work in Equatorial Guinea. The 170-day campaign is expected to begin in 2027 and will contribute approximately $80 million in backlog, excluding mobilization and demobilization fees.
Hubilu Venture Signs $600K M&A Deal with Finance of America Reverse LLC
Hubilu Venture Corporation, through its subsidiary Elata Investments, LLC, completed the acquisition of a real property asset located at 5717 4th Ave in Los Angeles for $600,000. The acquisition was financed in part by a $550,000 first position note from Orchard Funding bearing interest at 9.99% per annum.
Flex Ltd. provided a status update on the planned spin-off of its cloud and power infrastructure business into a new independent company named Axiom Solutions International, Inc. The company announced the expected board compositions for both entities post-separation and appointed Amy B. Schwetz as CFO of its RMS and ITS segments, with the expectation that she will become Flex CFO after the spin-off.
Ingram Micro is hosting its inaugural 2026 Capital Markets Day to outline its transformation into a B2B intelligent operating system and introduce a multi-year financial framework through 2029. The company established long-term targets including a net sales CAGR of 4-6% and a non-GAAP net income CAGR of 11-13%, while also reaffirming that Q3 2026 results are expected at the high end of previously provided guidance.
Earnings call
Sep 15, 2026, 11:15 AM ET
“For decades, our scale, reach, and relationships have made Ingram Micro a trusted partner across the global technology ecosystem. Today, we are entering a new chapter as we build on those strengths to create the industry’s B2B intelligent operating system at scale.”
Paul Bay, Ingram Micro’s Chief Executive Officer
“In the short term, for the third quarter of fiscal 2026 we expect to achieve results at the high end of the range of the guidance we provided on our second quarter earnings call in late July.”
Mike Zilis, Ingram Micro’s Chief Financial Officer
Anantha Ramamurti resigned from the Board of Directors of GSR IV Acquisition Corp. effective September 9, 2026, though he will remain the company's President and Chief Financial Officer. The resignation was a planned move to ensure the board remains majority independent in compliance with NASDAQ Listing Rule 5605(b).
Iridium Communications M&A Deal with Rocket Lab Corporation
Iridium Communications entered into a fourth amendment to its credit agreement to facilitate its pending merger with Rocket Lab Corporation. The amendment ensures the transaction does not trigger a 'Change of Control' default and secures lender consent for the merger, while adjusting interest rates and adding a downstream guarantee from Rocket Lab USA, Inc. upon closing.
Atkore Inc. announced the expiration of the HSR Act waiting period regarding its pending acquisition by Prysmian S.p.A. The expiration of the antitrust waiting period satisfies a key closing condition for the merger, which remains subject to stockholder approval and other customary conditions.
Hub Group appointed David P. Yeager as Chairman and Chief Executive Officer, effective immediately, returning him to the role he previously held from 1995 to 2022. The company also appointed Patrick O’Donnell as Chief Financial Officer and Treasurer as it continues to work through a financial restatement process for fiscal years 2023 and 2024.
Profusa, Inc. received a letter from Nasdaq confirming it has regained compliance with the minimum bid price and stockholders' equity requirements. As a result, the company will be subject to a one-year Mandatory Panel Monitor period, during which any further non-compliance with the equity rule will result in a prompt delisting determination without a cure period. The company intends to continue monitoring its status to maintain its listing on The Nasdaq Capital Market.
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions (AITX) issued a statement calling for clearer regulatory guardrails and data privacy boundaries in the AI-powered security industry. The company highlighted its own approach to data privacy, noting that its Robotic Assistance Devices (RAD) subsidiary maintains data in customer-specific environments rather than pooled surveillance networks and does not utilize facial recognition.
InnSuites Hospitality Trust received notice that NYSE American has accepted its compliance plan, granting an extension through December 24, 2027, to regain compliance with continued listing standards. The Trust recently increased stockholders' equity by $3 million and is exploring strategic alternatives, including a potential reverse merger, to meet the exchange's requirements.
FatPipe Inc. appointed Kanishka Ragula as Chief Financial Officer and Principal Accounting Officer, effective September 11, 2026, succeeding Eric Sherb who will remain as a consultant. Mr. Ragula, who previously served as the company's Director of Finance and has a background in technology investment banking at J.P. Morgan, is the son of the company's CEO and President.
Hyperliquid Strategies Inc entered into Amendment No. 3 to its existing ChEF Purchase Agreement with Chardan Capital Markets LLC. The amendment modifies the pricing formula for future share sales, setting the purchase price at 98.5% or 97.0% of the VWAP depending on the purchase type, effective after the first 160 million shares are sold.
Strive, Inc. maintained its annual dividend rate of 13.00% on its Variable Rate Series A Perpetual Preferred Stock (SATA). The board declared daily cash dividends of $0.0516 per share for each business day in October 2026, totaling $1.0836 per share for the month. The company noted that these distributions are expected to be treated as a tax-deferred recovery of capital as it does not expect to generate earnings and profits in the foreseeable future.